Ovarian Cancer — Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Citation(s)
A Phase I/II Study of Sorafenib in Combination With Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111